AR and metastatic prostate carcinoma: In conclusion, this extended analysis further reinforces the body of data on the substantial benefits of upfront targeting of the androgen receptor pathway using abiraterone acetate in all men with hormone‐sensitive metastatic prostate cancer, irrespective of metastatic disease risk group.